Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Weixiu Luo et al.|The Lancet Oncology|2017Cited by 122
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Aron Goldhirsch, Kathryn P. Gray et al.|Journal of Clinical Oncology|2016Cited by 77
P5-22-01: Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic HER2−Positive Breast Cancer (BC) To Evaluate Alterations in Molecular Biomarkers (BM): Preliminary Results of SHERsig (Study of HER2 Signature in Metastatic Breast Cancer) a Prospective Phase II Study.Arlene Chan, Ian O. Ellis, Jacquie Chirgwin et al.|Cancer Research|2011Cited by 0